Equities

Verici DX PLC

VRCI:LSE

Verici DX PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.725
  • Today's Change0.00 / 0.00%
  • Shares traded887.17k
  • 1 Year change-80.67%
  • Beta0.3790
Data delayed at least 20 minutes, as of Feb 06 2026 16:17 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Verici Dx plc is a developer of advanced clinical diagnostics for organ transplants. The Company develops a suite of tests forming a kidney transplant platform for personalized patients and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including subclinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure.

  • Revenue in GBP (TTM)1.41m
  • Net income in GBP-5.63m
  • Incorporated2020
  • Employees15.00
  • Location
    Verici DX PLC393 Nichol Mill Lane, Suite 200FRANKLIN 37067United StatesUSA
  • Websitehttps://vericidx.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Genincode PLC2.91m-4.97m3.30m36.003.30m36.00
Surgical Innovations Group Plc11.92m-1.44m4.20m88.004.20m88.00
Cambridge Nutritional Sciences PLC8.06m1.37m4.76m84.004.76m84.00
Feedback plc885.62k-7.32m4.89m28.004.89m28.00
Proteome Sciences plc4.53m-3.33m6.16m36.006.16m36.00
Rua Life Sciences PLC5.17m-850.00k9.00m33.009.00m33.00
Verici DX PLC1.41m-5.63m10.97m15.0010.97m15.00
Genedrive PLC954.00k-5.23m11.84m43.0011.84m43.00
Cellbxhealth PLC2.62m-15.78m11.96m119.0011.96m119.00
Abingdon Health PLC8.43m-3.42m15.06m121.0015.06m121.00
Inspiration Healthcare Group PLC45.20m-11.44m15.69m214.0015.69m214.00
Renalytix PLC2.22m-15.08m24.47m45.0024.47m45.00
Aptamer Group PLC1.20m-2.42m25.62m31.0025.62m31.00
Data as of Feb 06 2026. Currency figures normalised to Verici DX PLC's reporting currency: UK Pound GBX

Institutional shareholders

42.08%Per cent of shares held by top holders
HolderShares% Held
Harwood Capital LLPas of 30 Sep 2025193.07m12.76%
Canaccord Genuity Wealth Ltd.as of 30 Jul 2025157.13m10.38%
Unicorn Asset Management Ltd.as of 30 Jul 2025119.62m7.90%
UBS Asset Management (UK) Ltd.as of 30 Jul 2025118.31m7.82%
Octopus Investments Ltd.as of 24 Jul 202521.48m1.42%
Hargreaves Lansdown Asset Management Ltd.as of 31 Mar 202517.36m1.15%
Rathbones Investment Management Ltd.as of 31 Mar 20259.25m0.61%
Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 2025323.13k0.02%
Foresight Group LLP (Investment Management)as of 31 Mar 2025294.69k0.02%
More ▼
Data from 30 Sep 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.